for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

399.65USD

Change

2.00(+0.50%)

Volume

339,780

Today's Range

395.31

 - 

402.21

52 Week Range

271.37

 - 

442.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Regeneron Reports Q4 Non-GAAP Earnings Per Share $7.50

Feb 6 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL AND OPERATING RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $7.50.Q4 GAAP EARNINGS PER SHARE $6.93.Q4 EARNINGS PER SHARE ESTIMATE $6.92 -- REFINITIV IBES DATA.Q4 2019 REVENUES INCREASED 13% TO $2.17 BILLION.Q4 EYLEA U.S. NET SALES INCREASED 13% TO $1.22 BILLION.CO AND SANOFI ANNOUNCED INTENT TO RESTRUCTURE ANTIBODY COLLABORATION FOR KEVZARA AND PRALUENT.CO WILL PROVIDE FINANCIAL GUIDANCE FOR FULL YEAR 2020 BY END OF Q1 OF 2020.QTRLY TOTAL SANOFI COLLABORATION REVENUE $427.1 MILLION VERSUS $427.6 MILLION.IN THE QUARTER, GLOBAL NET SALES OF PRALUENT RECORDED BY SANOFI WERE $81.4 MILLION, COMPARED TO $ 93.2 MILLION.IN THE QUARTER, GLOBAL NET SALES OF DUPIXENT RECORDED BY SANOFI WERE $751.5 MILLION, COMPARED TO $318.8 MILLION.Q4 REVENUE VIEW $2.11 BILLION -- REFINITIV IBES DATA.

Regeneron Says FDA Has Accepted For Priority Review Dupixent® (Dupilumab) For Children Aged 6 To 11 Years With Moderate-To-Severe Atopic Dermatitis

Jan 28 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::FDA ACCEPTS FOR PRIORITY REVIEW DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.REGENERON PHARMACEUTICALS INC - IF APPROVED, DUPIXENT WOULD BE FIRST BIOLOGIC MEDICINE AVAILABLE IN U.S. FOR THESE CHILDREN.REGENERON PHARMACEUTICALS INC - TARGET ACTION DATE FOR FDA DECISION IS MAY 26, 2020.REGENERON PHARMACEUTICALS INC - SBLA IS SUPPORTED BY DATA THAT INCLUDES PIVOTAL PHASE 3 RESULTS ON EFFICACY.REGENERON PHARMACEUTICALS -SBLA ALSO SUPPORTED BY SAFETY OF DUPIXENT COMBINED WITH TOPICAL CORTICOSTEROIDS IN CHILDREN WITH SEVERE ATOPIC DERMATITIS.

Regeneron Pharmaceuticals- Preliminary U.S. Net Product Sales Of Eylea Injection Of About $4.64 Bln For 2019

Jan 13 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON PHARMACEUTICALS INC - PRELIMINARY U.S. NET PRODUCT SALES OF EYLEA INJECTION OF ABOUT $4.64 BILLION FOR 2019.REGENERON PHARMACEUTICALS INC SEES PRELIMINARY U.S. NET PRODUCT SALES OF EYLEA INJECTION OF $1.22 BILLION FOR Q4 2019 - PRESENTATION.

Regeneron Announces Encouraging Garetosmab Phase 2 Results In Patients With Ultra-Rare Debilitating Bone Disease

Jan 9 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON ANNOUNCES ENCOURAGING GARETOSMAB PHASE 2 RESULTS IN PATIENTS WITH ULTRA-RARE DEBILITATING BONE DISEASE.REGENERON PHARMACEUTICALS - PLANS TO DISCUSS REGULATORY SUBMISSION WITH REGULATORY AUTHORITIES; PEDIATRIC TRIAL PLANNING UNDERWAY.REGENERON PHARMACEUTICALS - INVESTIGATOR-REPORTED ADVERSE EVENTS OF FLARE-UPS WERE 10% FOR GARETOSMAB AND 42% FOR PLACEBO IN TRIAL.

Regeneron And Sanofi Announce Intent To Restructure Antibody Collaboration For Kevzara And Praluent

Dec 10 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON AND SANOFI ANNOUNCE INTENT TO RESTRUCTURE ANTIBODY COLLABORATION FOR KEVZARA (SARILUMAB) AND PRALUENT (ALIROCUMAB).REGENERON PHARMACEUTICALS INC - SANOFI IS EXPECTED TO GAIN SOLE GLOBAL RIGHTS TO KEVZARA AND SOLE EX-U.S. RIGHTS TO PRALUENT.REGENERON PHARMACEUTICALS - EACH PARTY WILL BE SOLELY RESPONSIBLE FOR FUNDING DEVELOPMENT & COMMERCIALIZATION EXPENSES IN THEIR RESPECTIVE TERRITORIES.REGENERON PHARMACEUTICALS INC - REGENERON IS EXPECTED TO GAIN SOLE U.S. RIGHTS TO PRALUENT..REGENERON PHARMACEUTICALS - EXISTING COLLABORATION RELATING TO DUPIXENT WILL REMAIN UNCHANGED FOLLOWING RESTRUCTURING.

Regeneron Announces Positive Topline Data From Rare Blood Disorder Study

Dec 5 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA WITH ANTI-C5 ANTIBODY POZELIMAB IN PATIENTS WITH A RARE BLOOD DISORDER.REGENERON PHARMACEUTICALS INC - SECOND PART OF PHASE 2 TRIAL INITIATED.REGENERON PHARMAC- POZELIMAB REDUCED ABNORMAL DESTRUCTION OF RED BLOOD CELLS WITH PATIENTS IN INITIAL COHORT ACHIEVING NORMAL LEVELS OF BLOOD BIOMARKER.REGENERON PHARMACEUTICALS INC - IN EARLIER PHASE 1 TRIAL, ONLY SERIOUS AE WAS SALPINGITIS IN A SINGLE PARTICIPANT.

Regeneron And Vyriad Announce Strategic Agreement For Discovery And Development Of New Oncolytic Virus Treatments For Cancer

Nov 6 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON AND VYRIAD ANNOUNCE STRATEGIC AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NEW ONCOLYTIC VIRUS TREATMENTS FOR CANCER.REGENERON PHARMACEUTICALS INC - PHASE 2 TRIAL WILL EVALUATE COMBINATION OF PD-1 INHIBITOR LIBTAYO AND ONCOLYTIC VIRUS VOYAGER-V1.REGENERON PHARMACEUTICALS INC - VYRIAD TO RECEIVE UPFRONT PAYMENT AND EQUITY INVESTMENT FROM CO.REGENERON PHARMACEUTICALS INC - AGREEMENT INCLUDES A PHASE 2 CLINICAL STUDY, SLATED TO BEGIN IN 2020.

Regeneron Says Co, Unit Received Civil Investigative Demand From U.S. DOJ In September

Nov 5 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON PHARMACEUTICALS - IN SEPT., CO & UNIT RECEIVED A CIVIL INVESTIGATIVE DEMAND FROM THE U.S. DOJ PURSUANT TO THE FEDERAL FALSE CLAIMS ACT.REGENERON PHARMACEUTICALS - CIDS FROM U.S. DOJ RELATE TO EYLEA, PRALUENT,DUPIXENT, ZALTRAP, ARCALYST, KEVZARA, COVER PERIOD FROM JAN. 2015 TO PRESENT.REGENERON PHARMACEUTICALS - CIDS FROM U.S. DOJ RELATE TO REMUNERATION PAID TO PHYSICIANS AS CONSULTING FEES, ADVISORY BOARDS, SPEAKER FEES.REGENERON - CIDS FROM U.S. DOJ RELATE TO PAYMENT OR REIMBURSEMENT FOR TRAVEL, ENTERTAINMENT ALLEGEDLY IN VIOLATION OF FEDERAL ANTI-KICKBACK STATUTE.REGENERON PHARMACEUTICALS - IS COOPERATING WITH INVESTIGATION BY THE U.S. DOJ.

Regeneron Provides Updates On Phase 3 Libtayo Development Program In Advanced Non-Small Cell Lung Cancer

Nov 5 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON PROVIDES UPDATES ON PHASE 3 LIBTAYO® (CEMIPLIMAB) DEVELOPMENT PROGRAM IN ADVANCED NON-SMALL CELL LUNG CANCER.REGENERON PHARMACEUTICALS INC - CURRENTLY RECRUITING PATIENTS IN TWO PHASE 3 TRIALS IN FIRST-LINE NSCLC.REGENERON PHARMACEUTICALS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED TRIAL SHOULD CONTINUE AS PLANNED.REGENERON PHARMACEUTICALS INC - NEXT EVENT-DRIVEN INTERIM ANALYSIS FOR OS IS ANTICIPATED IN 2020.

Regeneron Q3 GAAP Earnings Per Share $5.86

Nov 5 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON REPORTS THIRD QUARTER 2019 FINANCIAL AND OPERATING RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $6.67.Q3 GAAP EARNINGS PER SHARE $5.86.Q3 EARNINGS PER SHARE ESTIMATE $6.36 -- REFINITIV IBES DATA.Q3 EYLEA U.S. NET SALES INCREASED 16% TO $1.19 BILLION VERSUS Q3 2018.QTRLY REVENUES INCREASED 23% TO $2.05 BILLION.Q3 EYLEA U.S. NET SALES INCREASED 16% TO $1.19 BILLION VERSUS Q3 2018.SEES FY2019 CAPEX $390 MILLION-$420 MILLION.SAYS INITIATION OF A $1 BILLION SHARE REPURCHASE PROGRAM.Q3 GLOBAL NET SALES OF PRALUENT RECORDED BY SANOFI WERE $69.7 MILLION, COMPARED TO $80.2 MILLION.SHARE REPURCHASE PROGRAM HAS NO TIME LIMIT AND CAN BE DISCONTINUED AT ANY TIME.SEES FY 2019 GAAP SANOFI COLLABORATION REVENUE $490 MILLION-$510 MILLION.QTRLY GLOBAL NET SALES OF DUPIXENT RECORDED BY SANOFI WERE $633.1 MILLION VERSUS $262.6 MILLION.Q3 EARNINGS PER SHARE VIEW $6.36, REVENUE VIEW $1.99 BILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up